To date, ten patients with non-prostate solid cancers (salivary gland cancer, glioblastoma, thyroid cancer, hepatocellular carcinoma, and breast cancer) have been treated with PSMA-RLT and some beneficial effects were seen, making this an interesting topic for further exploration. This evidence concerns the gene FOLH1 and breast carcinoma.